Blood safety is gaining renewed attention after Cerus Corporation reported that its Phase 3 RedeS trial met its primary efficacy goal for pathogen-reduced red blood cells.
The company's INTERCEPT-treated cells were non-inferior to conventional red blood cells in the measure of post-transfusion haemoglobin increase, opening a potential new application for pathogen reduction.
The findings matter beyond the trial because India continues to strengthen its blood transfusion services, where screening, processing and reliable supply remain central priorities.
The development raises a wider question: could red cell pathogen reduction add another protective layer to blood systems across India and other health systems.
Cerus' Phase 3 RedeS trial represents an important development in the application of pathogen-reduction technology to red blood cell transfusions.
The INTERCEPT Blood System is designed to reduce the risk of viruses, bacteria and other pathogens in donated blood products through a treatment process that targets the genetic material of pathogens.
The RedeS study compared INTERCEPT-treated red blood cells with conventional red blood cells in patients requiring transfusion support. Its primary efficacy endpoint measured adjusted haemoglobin increment, an indicator of how effectively a transfusion increases haemoglobin levels.
The adjusted haemoglobin increment was 1.996 g/dL in the INTERCEPT group, compared with 2.050 g/dL in the conventional treatment group. The estimated difference was -0.054 g/dL, meeting the predefined non-inferiority threshold, with a p-value of 0.004.
The findings indicate that pathogen-treated red blood cells performed within the study's predefined efficacy limits compared with conventional cells.
Treatment-related adverse events were reported in 3.4 percent of the INTERCEPT group, compared with 2.5 percent in the control group. Six patients, representing 2.2 percent of the INTERCEPT safety population of 267, developed low-titre, transient INTERCEPT-specific antibodies.
Also Read: India's Drug Pricing Architecture: Why the Rules Keep Expanding
The development comes at a time when India is working to strengthen its blood transfusion infrastructure and improve access to safe blood products.
According to the Directorate General of Health Services, India's annual blood requirement is estimated at 14.6 million units.
The country's existing framework requires donated blood to undergo screening for five transfusion-transmissible infections: HIV/AIDS, Hepatitis B, Hepatitis C, syphilis and malaria.
While these screening measures remain essential, emerging pathogen risks highlight the importance of exploring additional approaches to ensure blood safety.
The Ministry of Health and Family Welfare convened a national-level review of blood transfusion services on April 22, 2026, involving representatives from all 36 states and Union Territories.
The review focused on improving donor screening, blood collection, testing, processing, storage and reporting.
The government also outlined a roadmap for universal access to safe blood by December 2026, with complete onboarding of blood centers onto eRaktKosh and the Blood Bank Management System (BBMS) emphasized for real-time monitoring.
Despite the positive Phase 3 results, Cerus' INTERCEPT red blood cell system remains investigational in the United States and has not received regulatory approval from the US FDA.
Cerus expects the complete study results, including secondary endpoints, to be submitted to a peer-reviewed scientific journal and presented at upcoming scientific meetings. The regulatory outcome will be important in determining whether the technology can move towards wider clinical adoption.
For India, the development provides an opportunity to follow advances in blood transfusion technology while assessing their relevance to domestic healthcare infrastructure.
.jpg)
